Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy
- 1 January 2022
- journal article
- review article
- Vol. 10 (3) , 142-153
Abstract
Nanomedicine is an evolving field of scientific research with unique advantages and challenges for the detection and treatment of medical diseases. Since 1995, the FDA has approved the administration of nanoparticle-based therapies. The initial generation of nanoparticles relied on an enhanced permeability and retention effect, associated with an increased penetrability of tumor related blood vessels. With increasing knowledge of biomarkers and molecular targets, active targeting of circulating tumor cells by nanoparticles provides an exciting area for application. The selective targeting of prostate cancer cells using a nanotechnology-based mechanism has the potential to optimize the delivery of therapeutic payloads directly to prostate cancer cells while minimizing systemic toxicities. The molecular targets that have been studied include prostate specific membrane antigen, gastrin releasing peptide protein, glucose related protein, CD44, claudin, C-X-C chemokine receptor type 4 (CXCR-4), and adenosine. The clinical potential for nanoparticle-based therapies is supported by several studies that have progressed past the preclinical stage into clinical trials. In this review, we present the molecular biomarkers that have been targeted by ligands conjugated to the surface of nanoparticles for prostate cancer imaging and therapy.Keywords
This publication has 63 references indexed in Scilit:
- A peptide derived from phage display library exhibits anti-tumor activity by targeting GRP78 in gastric cancer multidrug resistance cellsCancer Letters, 2013
- A2B adenosine receptor blockade inhibits growth of prostate cancer cellsPurinergic Signalling, 2013
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinomaDiagnostic Pathology, 2011
- Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted deliveryJournal of Controlled Release, 2010
- Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cellsJournal of Nanoparticle Research, 2009
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences, 2008
- Aptamer-Targeted Gold Nanoparticles As Molecular-Specific Contrast Agents for Reflectance ImagingBioconjugate Chemistry, 2008
- Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug deliveryBiomaterials, 2007
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences, 2006